Autogenic Drainage Versus Mechanical Percussion in Children With Cystic Fibrosis
NCT07729787
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Multan Khurd, Punjab Province, Pakistan
View Trial DetailsNCT Number: NCT07312734
Sputum culture has been the best approach to detect harmful bacteria in the lungs of people with cystic fibrosis (CF). With the widespread use of new CF therapies (like Trikafta and Alyftrak), it is more difficult for people with CF to produce sputum even though they still have harmful bacteria in their lungs. The SEND-CF study is being done to see if there are other ways to detect harmful bacteria in the lungs.
Interested in participating?
Request Info16 year and older
All sexes
Observational
University of California San Diego, La Jolla, California, United States
People with cystic fibrosis (CF) often get lung infections that can make their breathing worse and make their lungs weaker over time. Sputum culture is usually analyzed to find these infections. Currently, many people with CF are using CFTR modulators. These medicines help, but they also make it harder for people to cough up sputum. Even though people with CF are making less sputum, lung infections are still a problem. New ways are needed to check for infections without using sputum.
The SEND-CF study wants to gather health information and samples from people with CF in order to find new and better ways to spot harmful bacteria in the lungs. Participants, who typically are able to produce sputum who consent to participate will be asked to provide samples including sputum, saliva, serum, plasma, buffy coat, urine, and whole blood. Some participants will also provide breath samples for a sub-study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline Visit
Specimens (including sputum, saliva, blood, urine, and breath (for the Owlstone Device Sub-Study)) will be collected at the Study Visit. These specimens will be stored at a biorepository and be made available to the research community to test and validate diagnostic assays for the detection of CF pathogens.
Contact information is provided by the study sponsor or research team.
Anna Mead
CONTACT
Nikita Midamba
CONTACT
Chris Goss
Other
Study to Enable New Diagnostics for Pulmonary Microbes in People With CF (SEND-CF)
Acronym: SEND-CF
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07729787
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Multan Khurd, Punjab Province, Pakistan
View Trial DetailsNCT07450547
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Long Beach, California, United States
View Trial DetailsNCT07275905
Achromobacter Infection, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
San Diego, California, United States
View Trial DetailsNCT07048574
Anxiety Disorders, Behavior
Orange, California, United States
View Trial Details